Baicalin inhibits influenza virus A replication via activation of type I IFN signaling by reducing miR‑146a

Li,Rui; Wang,Lianxin

doi:10.3892/mmr.2019.10743

Baicalin inhibits influenza virus A replication via activation of type I IFN signaling by reducing miR‑146a

Authors:
- Rui Li
- Lianxin Wang
View Affiliations

Affiliations: Department of Traditional Chinese Medicine, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing 400014, P.R. China, Institute of Basic Research of Traditional Chinese Medicine in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, P.R. China
Published online on: October 15, 2019 https://doi.org/10.3892/mmr.2019.10743
Pages: 5041-5049
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Influenza virus A (IVA) is one of the predominant causative agents of the seasonal flu and has become an important cause of morbidity worldwide. Great efforts have been paid to develop vaccines against IVA. However, due to antigenic drift in influenza virus A and rapid emergence of drug‑resistant strains, current available vaccines or anti‑IVA chemotherapeutics are consistently inefficient. Hence, various more broadly effective drugs have become important for the prevention and treatment of IVA. Of these drugs, baicalin, a flavonoid isolated from Radix Scutellaria, is a promising example. However, little is known in regards to its pharmacological mechanism. Here, it was demonstrated that baicalin inhibits the H1N1 and H3N2 viruses in A549 cells. Subsequently, it was found that miR‑146a was markedly downregulated by treatment of baicalin. Additionally, further experiments revealed that miR‑146a was able to promote the replication of H1N1 and H3N2 by targeting TNF receptor‑associated factor 6 (TRAF6), a pivotal adaptor in the interferon (IFN) production signaling pathway, to downregulate type I IFN production, and enrichment of miR‑146a eliminated the anti‑IVA effects of baicalin on the H1N1 and H3N2 viruses. Additionally, in vivo experiments demonstrated that baicalin could protect mice during H1N1 infection. Taken together, our findings firstly illustrated the anti‑IVA molecular mechanism of baicalin and provide new evidence for targeting miRNAs to prevent and treat viral infection, such as the H1N1 and H3N2 viruses.

View Figures

View References

1	García-García J and Ramos C: Influenza, an existing public health problem. Salud Publica Mex. 48:244–267. 2006.(In Spanish). PubMed/NCBI
2	Bauer TT, Ewig S, Rodloff AC and Muller EE: Acute respiratory distress syndrome and pneumonia: A comprehensive review of clinical data. Clin Infect Dis. 43:748–756. 2006. View Article : Google Scholar : PubMed/NCBI
3	Bai GR, Chittaganpitch M, Kanai Y, Li YG, Auwanit W, Ikuta K and Sawanpanyalert P: Amantadine- and oseltamivir-resistant variants of influenza A viruses in Thailand. Biochem Biophys Res Commun. 390:897–901. 2009. View Article : Google Scholar : PubMed/NCBI
4	Terán-Cabanillas E, Montalvo-Corral M, Silva-Campa E, Caire-Juvera G, Moya-Camarena SY and Hernández J: Production of interferon α and β, pro-inflammatory cytokines and the expression of suppressor of cytokine signaling (SOCS) in obese subjects infected with influenza A/H1N1. Clin Nutr. 33:922–926. 2014. View Article : Google Scholar : PubMed/NCBI
5	Zhang F, Sun X, Zhu Y and Qin W: Downregulation of miR-146a inhibits influenza A virus replication by enhancing the type I interferon response in vitro and in vivo. Biomed Pharmacother. 111:740–750. 2019. View Article : Google Scholar : PubMed/NCBI
6	Kandel R and Hartshorn KL: Novel strategies for prevention and treatment of influenza. Expert Opin Ther Targets. 9:1–22. 2005. View Article : Google Scholar : PubMed/NCBI
7	Beigel J and Bray M: Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 78:91–102. 2008. View Article : Google Scholar : PubMed/NCBI
8	Moazed D: Small RNAs in transcriptional gene silencing and genome defence. Nature. 457:413–420. 2009. View Article : Google Scholar : PubMed/NCBI
9	Baltimore D, Boldin MP, O'Connell RM, Rao DS and Taganov KD: MicroRNAs: New regulators of immune cell development and function. Nat Immunol. 9:839–845. 2008. View Article : Google Scholar : PubMed/NCBI
10	O'Neill LA, Sheedy FJ and McCoy CE: MicroRNAs: The fine-tuners of toll-like receptor signalling. Nat Rev Immunol. 11:163–175. 2011. View Article : Google Scholar : PubMed/NCBI
11	Yarbrough ML, Zhang K, Sakthivel R, Forst CV, Posner BA, Barber GN, White MA and Fontoura BM: Primate-specific miR-576-3p sets host defense signalling threshold. Nat Commun. 5:49632014. View Article : Google Scholar : PubMed/NCBI
12	Jopling CL, Schutz S and Sarnow P: Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe. 4:77–85. 2008. View Article : Google Scholar : PubMed/NCBI
13	Lagos D, Pollara G, Henderson S, Gratrix F, Fabani M, Milne RS, Gotch F and Boshoff C: miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. Nat Cell Biol. 12:513–519. 2010. View Article : Google Scholar : PubMed/NCBI
14	Su RC, Sivro A, Kimani J, Jaoko W, Plummer FA and Ball TB: Epigenetic control of IRF1 responses in HIV-exposed seronegative versus HIV-susceptible individuals. Blood. 117:2649–2657. 2011. View Article : Google Scholar : PubMed/NCBI
15	Hu Y, Jiang L, Lai W, Qin Y, Zhang T, Wang S and Ye X: MicroRNA-33a disturbs influenza A virus replication by targeting ARCN1 and inhibiting viral ribonucleoprotein activity. J Gen Virol. 97:27–38. 2016. View Article : Google Scholar : PubMed/NCBI
16	Hayman A, Comely S, Lackenby A, Murphy S, McCauley J, Goodbourn S and Barclay W: Variation in the ability of human influenza A viruses to induce and inhibit the IFN-beta pathway. Virology. 347:52–64. 2006. View Article : Google Scholar : PubMed/NCBI
17	Yan Y, Tan KS, Li C, Tran T, Chao SS, Sugrue RJ, Shi L, Chow VT and Wang DY: Human nasal epithelial cells derived from multiple subjects exhibit differential responses to H3N2 influenza virus infection in vitro. J Allergy Clin Immunol. 138:276–281.e15. 2016. View Article : Google Scholar : PubMed/NCBI
18	Terrier O, Textoris J, Carron C, Marcel V, Bourdon JC and Rosa-Calatrava M: Host microRNA molecular signatures associated with human H1N1 and H3N2 influenza A viruses reveal an unanticipated antiviral activity for miR-146a. J Gen Virol. 94:985–995. 2013. View Article : Google Scholar : PubMed/NCBI
19	Lin CC and Shieh DE: The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am J Chin Med. 24:31–36. 1996. View Article : Google Scholar : PubMed/NCBI
20	Zhou QM, Wang S, Zhang H, Lu YY, Wang XF, Motoo Y and Su SB: The combination of baicalin and baicalein enhances apoptosis via the ERK/p38 MAPK pathway in human breast cancer cells. Acta Pharmacol Sin. 30:1648–1658. 2009. View Article : Google Scholar : PubMed/NCBI
21	Li CT, Zhang WP, Fang SH, Lu YB, Zhang LH, Qi LL, Huang XQ, Huang XJ and Wei EQ: Baicalin attenuates oxygen-glucose deprivation-induced injury by inhibiting oxidative stress-mediated 5-lipoxygenase activation in PC12 cells. Acta Pharmacol Sin. 31:137–144. 2010. View Article : Google Scholar : PubMed/NCBI
22	Xu G, Dou J, Zhang L, Guo Q and Zhou C: Inhibitory effects of baicalein on the influenza virus in vivo is determined by baicalin in the serum. Biol Pharm Bull. 33:238–243. 2010. View Article : Google Scholar : PubMed/NCBI
23	Zhu HY, Han L, Shi XL, Wang BL, Huang H, Wang X, Chen DF, Ju DW and Feng MQ: Baicalin inhibits autophagy induced by influenza A virus H3N2. Antiviral Res. 113:62–70. 2015. View Article : Google Scholar : PubMed/NCBI
24	Chu M, Xu L, Zhang MB, Chu ZY and Wang YD: Role of baicalin in anti-influenza virus a as a potent inducer of IFN-gamma. Biomed Res Int. 2015:2636302015. View Article : Google Scholar : PubMed/NCBI
25	Ding Y, Dou J, Teng Z, Yu J, Wang T, Lu N, Wang H and Zhou C: Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase. Arch Virol. 159:3269–3278. 2014. View Article : Google Scholar : PubMed/NCBI
26	Lee YR, Yeh SF, Ruan XM, Zhang H, Hsu SD, Huang HD, Hsieh CC, Lin YS, Yeh TM, Liu HS and Gan DD: Honeysuckle aqueous extract and induced let-7a suppress dengue virus type 2 replication and pathogenesis. J Ethnopharmacol. 198:109–121. 2017. View Article : Google Scholar : PubMed/NCBI
27	Shibata C, Ohno M, Otsuka M, Kishikawa T, Goto K, Muroyama R, Kato N, Yoshikawa T, Takata A and Koike K: The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels. Virology. 462:42–48. 2014. View Article : Google Scholar : PubMed/NCBI
28	Wang L, Zhang R, Chen J, Wu Q and Kuang Z: Baicalin protects against TNF-α-induced injury by down-regulating miR-191a that targets the tight junction protein ZO-1 in IEC-6 cells. Biol Pharm Bull. 40:435–443. 2017. View Article : Google Scholar : PubMed/NCBI
29	Wang J, Masika J, Zhou J, Wang J, Zhu M, Luo H, Hu X, Zhang L, Tang M, Gao L, et al: Traditional Chinese medicine baicalin suppresses mESCs proliferation through inhibition of miR-294 expression. Cell Physiol Biochem. 35:1868–1876. 2015. View Article : Google Scholar : PubMed/NCBI
30	Xu Y, Zhou B, Wu D, Yin Z and Luo D: Baicalin modulates microRNA expression in UVB irradiated mouse skin. J Biomed Res. 26:125–134. 2012. View Article : Google Scholar : PubMed/NCBI
31	Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K and Taniguchi T: Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature. 424:516–523. 2003. View Article : Google Scholar : PubMed/NCBI
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
33	Liu XX, Yu DD, Chen MJ, Sun T, Li G, Huang WJ, Nie H, Wang C, Zhang YX, Gong Q and Ren BX: Hesperidin ameliorates lipopolysaccharide-induced acute lung injury in mice by inhibiting HMGB1 release. Int Immunopharmacol. 25:370–376. 2015. View Article : Google Scholar : PubMed/NCBI
34	Wu S, He L, Li Y, Wang T, Feng L, Jiang L, Zhang P and Huang X: miR-146a facilitates replication of dengue virus by dampening interferon induction by targeting TRAF6. J Infect. 67:329–341. 2013. View Article : Google Scholar : PubMed/NCBI
35	Yoshida R, Takaesu G, Yoshida H, Okamoto F, Yoshioka T, Choi Y, Akira S, Kawai T, Yoshimura A and Kobayashi T: TRAF6 and MEKK1 play a pivotal role in the RIG-I-like helicase antiviral pathway. J Biol Chem. 283:36211–36220. 2008. View Article : Google Scholar : PubMed/NCBI
36	Wan Q, Wang H, Han X, Lin Y and Yang Y, Gu L, Zhao J, Wang L, Huang L, Li Y and Yang Y: Baicalin inhibits TLR7/MYD88 signaling pathway activation to suppress lung inflammation in mice infected with influenza A virus. Biomed Rep. 2:437–441. 2014. View Article : Google Scholar : PubMed/NCBI
37	Nayak MK, Agrawal AS, Bose S, Naskar S, Bhowmick R, Chakrabarti S, Sarkar S and Chawla-Sarkar M: Antiviral activity of baicalin against influenza virus H1N1-pdm09 is due to modulation of NS1-mediated cellular innate immune responses. J Antimicrob Chemother. 69:1298–1310. 2014. View Article : Google Scholar : PubMed/NCBI
38	Taganov KD, Boldin MP, Chang KJ and Baltimore D: NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 103:12481–12486. 2006. View Article : Google Scholar : PubMed/NCBI
39	Farzan SF, Karagas MR, Christensen BC, Li Z, Kuriger JK and Nelson HH; New Hampshire Skin Cancer Study, : RNASEL and MIR146A SNP-SNP interaction as a susceptibility factor for non-melanoma skin cancer. PLoS One. 9:e936022014. View Article : Google Scholar : PubMed/NCBI
40	Khorrami S, Zavaran Hosseini A, Mowla SJ, Soleimani M, Rakhshani N and Malekzadeh R: MicroRNA-146a induces immune suppression and drug-resistant colorectal cancer cells. Tumour Biol. 39:10104283176983652017. View Article : Google Scholar : PubMed/NCBI
41	Pu J, Wu S, Xie H, Li Y, Yang Z, Wu X and Huang X: miR-146a inhibits dengue-virus-induced autophagy by targeting TRAF6. Arch Virol. 162:3645–3659. 2017. View Article : Google Scholar : PubMed/NCBI
42	Deng M, Du G, Zhao J and Du X: miR-146a negatively regulates the induction of proinflammatory cytokines in response to Japanese encephalitis virus infection in microglial cells. Arch Virol. 162:1495–1505. 2017. View Article : Google Scholar : PubMed/NCBI
43	Bandiera S, Pernot S, El Saghire H, Durand SC, Thumann C, Crouchet E, Ye T, Fofana I, Oudot MA, Barths J, et al: Hepatitis C Virus-induced upregulation of MicroRNA miR-146a-5p in hepatocytes promotes viral infection and deregulates metabolic pathways associated with liver disease pathogenesis. J Virol. 90:6387–6400. 2016. View Article : Google Scholar : PubMed/NCBI
44	Deng Y, Yan Y, Tan KS, Liu J, Chow VT, Tao ZZ and Wang DY: MicroRNA-146a induction during influenza H3N2 virus infection targets and regulates TRAF6 levels in human nasal epithelial cells (hNECs). Exp Cell Res. 352:184–192. 2017. View Article : Google Scholar : PubMed/NCBI